Anavex reports Q1 EPS (6c) vs. (14c) last year

“As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blarcamesine in early Alzheimer’s disease. Based on our commitment to improving the lives of patients with neurological disorders, we remain excited about the therapeutic potential of oral blarcamesine. We look forward to working with the regulatory agencies in Europe and the U.S. to advance oral blarcamesine as a potential new treatment option for patients.” said Christopher U. Missling, PhD, President and CEO of Anavex (AVXL). “An estimated 7.2 million people in the U.S. and 7 million in Europe are living with Alzheimer’s disease. Our mission is to develop targeted, orally delivered therapies aimed at a range of CNS related diseases, and specifically early-stage Alzheimer’s, where intervention may have the greatest impact.”